Record Information |
---|
Version | 5.0 |
---|
Status | Detected but not Quantified |
---|
Creation Date | 2021-09-11 18:45:34 UTC |
---|
Update Date | 2021-09-26 23:14:15 UTC |
---|
HMDB ID | HMDB0257719 |
---|
Secondary Accession Numbers | None |
---|
Metabolite Identification |
---|
Common Name | N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide |
---|
Description | N-{[5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl](hydroxy)methyl}-N-ethylformamide belongs to the class of organic compounds known as purine nucleosides. Purine nucleosides are compounds comprising a purine base attached to a ribosyl or deoxyribosyl moiety. Based on a literature review very few articles have been published on N-{[5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl](hydroxy)methyl}-N-ethylformamide. This compound has been identified in human blood as reported by (PMID: 31557052 ). N-[[(2s,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-n-ethylformamide is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources. |
---|
Structure | CCN(C=O)C(O)C1OC(C(O)C1O)N1C=NC2=C1N=CN=C2N InChI=1S/C13H18N6O5/c1-2-18(5-20)12(23)9-7(21)8(22)13(24-9)19-4-17-6-10(14)15-3-16-11(6)19/h3-5,7-9,12-13,21-23H,2H2,1H3,(H2,14,15,16) |
---|
Synonyms | Not Available |
---|
Chemical Formula | C13H18N6O5 |
---|
Average Molecular Weight | 338.324 |
---|
Monoisotopic Molecular Weight | 338.133867704 |
---|
IUPAC Name | N-{[5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl](hydroxy)methyl}-N-ethylformamide |
---|
Traditional Name | N-{[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl](hydroxy)methyl}-N-ethylformamide |
---|
CAS Registry Number | Not Available |
---|
SMILES | CCN(C=O)C(O)C1OC(C(O)C1O)N1C=NC2=C1N=CN=C2N |
---|
InChI Identifier | InChI=1S/C13H18N6O5/c1-2-18(5-20)12(23)9-7(21)8(22)13(24-9)19-4-17-6-10(14)15-3-16-11(6)19/h3-5,7-9,12-13,21-23H,2H2,1H3,(H2,14,15,16) |
---|
InChI Key | MERBRPKLASHSEH-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as purine nucleosides. Purine nucleosides are compounds comprising a purine base attached to a ribosyl or deoxyribosyl moiety. |
---|
Kingdom | Organic compounds |
---|
Super Class | Nucleosides, nucleotides, and analogues |
---|
Class | Purine nucleosides |
---|
Sub Class | Not Available |
---|
Direct Parent | Purine nucleosides |
---|
Alternative Parents | |
---|
Substituents | - Purine nucleoside
- Glycosyl compound
- N-glycosyl compound
- 6-aminopurine
- Imidazopyrimidine
- Purine
- Aminopyrimidine
- N-substituted imidazole
- Imidolactam
- Pyrimidine
- Azole
- Imidazole
- Heteroaromatic compound
- Oxolane
- Tertiary carboxylic acid amide
- Secondary alcohol
- Amino acid or derivatives
- 1,2-diol
- Carboxamide group
- Carboxylic acid derivative
- Azacycle
- Organoheterocyclic compound
- Oxacycle
- Alkanolamine
- Alcohol
- Organic nitrogen compound
- Hydrocarbon derivative
- Organic oxide
- Carbonyl group
- Organic oxygen compound
- Amine
- Primary amine
- Organonitrogen compound
- Organooxygen compound
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | Not Available |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Not Available |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedMetabolite | SMILES | Kovats RI Value | Column Type | Reference |
---|
N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide | CCN(C=O)C(O)C1OC(C(O)C1O)N1C=NC2=C1N=CN=C2N | 3948.7 | Standard polar | 33892256 | N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide | CCN(C=O)C(O)C1OC(C(O)C1O)N1C=NC2=C1N=CN=C2N | 2305.5 | Standard non polar | 33892256 | N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide | CCN(C=O)C(O)C1OC(C(O)C1O)N1C=NC2=C1N=CN=C2N | 3205.6 | Semi standard non polar | 33892256 |
DerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide,4TMS,isomer #1 | CCN(C=O)C(O[Si](C)(C)C)C1OC(N2C=NC3=C(N[Si](C)(C)C)N=CN=C32)C(O[Si](C)(C)C)C1O[Si](C)(C)C | 3016.4 | Semi standard non polar | 33892256 | N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide,4TMS,isomer #1 | CCN(C=O)C(O[Si](C)(C)C)C1OC(N2C=NC3=C(N[Si](C)(C)C)N=CN=C32)C(O[Si](C)(C)C)C1O[Si](C)(C)C | 2997.7 | Standard non polar | 33892256 | N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide,4TMS,isomer #1 | CCN(C=O)C(O[Si](C)(C)C)C1OC(N2C=NC3=C(N[Si](C)(C)C)N=CN=C32)C(O[Si](C)(C)C)C1O[Si](C)(C)C | 4162.3 | Standard polar | 33892256 | N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide,4TMS,isomer #2 | CCN(C=O)C(O[Si](C)(C)C)C1OC(N2C=NC3=C(N([Si](C)(C)C)[Si](C)(C)C)N=CN=C32)C(O[Si](C)(C)C)C1O | 3050.6 | Semi standard non polar | 33892256 | N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide,4TMS,isomer #2 | CCN(C=O)C(O[Si](C)(C)C)C1OC(N2C=NC3=C(N([Si](C)(C)C)[Si](C)(C)C)N=CN=C32)C(O[Si](C)(C)C)C1O | 3110.7 | Standard non polar | 33892256 | N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide,4TMS,isomer #2 | CCN(C=O)C(O[Si](C)(C)C)C1OC(N2C=NC3=C(N([Si](C)(C)C)[Si](C)(C)C)N=CN=C32)C(O[Si](C)(C)C)C1O | 4052.1 | Standard polar | 33892256 | N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide,4TMS,isomer #3 | CCN(C=O)C(O[Si](C)(C)C)C1OC(N2C=NC3=C(N([Si](C)(C)C)[Si](C)(C)C)N=CN=C32)C(O)C1O[Si](C)(C)C | 3055.8 | Semi standard non polar | 33892256 | N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide,4TMS,isomer #3 | CCN(C=O)C(O[Si](C)(C)C)C1OC(N2C=NC3=C(N([Si](C)(C)C)[Si](C)(C)C)N=CN=C32)C(O)C1O[Si](C)(C)C | 3109.5 | Standard non polar | 33892256 | N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide,4TMS,isomer #3 | CCN(C=O)C(O[Si](C)(C)C)C1OC(N2C=NC3=C(N([Si](C)(C)C)[Si](C)(C)C)N=CN=C32)C(O)C1O[Si](C)(C)C | 4027.7 | Standard polar | 33892256 | N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide,4TMS,isomer #4 | CCN(C=O)C(O)C1OC(N2C=NC3=C(N([Si](C)(C)C)[Si](C)(C)C)N=CN=C32)C(O[Si](C)(C)C)C1O[Si](C)(C)C | 3060.8 | Semi standard non polar | 33892256 | N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide,4TMS,isomer #4 | CCN(C=O)C(O)C1OC(N2C=NC3=C(N([Si](C)(C)C)[Si](C)(C)C)N=CN=C32)C(O[Si](C)(C)C)C1O[Si](C)(C)C | 3124.2 | Standard non polar | 33892256 | N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide,4TMS,isomer #4 | CCN(C=O)C(O)C1OC(N2C=NC3=C(N([Si](C)(C)C)[Si](C)(C)C)N=CN=C32)C(O[Si](C)(C)C)C1O[Si](C)(C)C | 4089.2 | Standard polar | 33892256 | N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide,5TMS,isomer #1 | CCN(C=O)C(O[Si](C)(C)C)C1OC(N2C=NC3=C(N([Si](C)(C)C)[Si](C)(C)C)N=CN=C32)C(O[Si](C)(C)C)C1O[Si](C)(C)C | 3079.4 | Semi standard non polar | 33892256 | N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide,5TMS,isomer #1 | CCN(C=O)C(O[Si](C)(C)C)C1OC(N2C=NC3=C(N([Si](C)(C)C)[Si](C)(C)C)N=CN=C32)C(O[Si](C)(C)C)C1O[Si](C)(C)C | 3059.4 | Standard non polar | 33892256 | N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide,5TMS,isomer #1 | CCN(C=O)C(O[Si](C)(C)C)C1OC(N2C=NC3=C(N([Si](C)(C)C)[Si](C)(C)C)N=CN=C32)C(O[Si](C)(C)C)C1O[Si](C)(C)C | 3654.5 | Standard polar | 33892256 | N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide,4TBDMS,isomer #1 | CCN(C=O)C(O[Si](C)(C)C(C)(C)C)C1OC(N2C=NC3=C(N[Si](C)(C)C(C)(C)C)N=CN=C32)C(O[Si](C)(C)C(C)(C)C)C1O[Si](C)(C)C(C)(C)C | 3727.8 | Semi standard non polar | 33892256 | N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide,4TBDMS,isomer #1 | CCN(C=O)C(O[Si](C)(C)C(C)(C)C)C1OC(N2C=NC3=C(N[Si](C)(C)C(C)(C)C)N=CN=C32)C(O[Si](C)(C)C(C)(C)C)C1O[Si](C)(C)C(C)(C)C | 3785.8 | Standard non polar | 33892256 | N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide,4TBDMS,isomer #1 | CCN(C=O)C(O[Si](C)(C)C(C)(C)C)C1OC(N2C=NC3=C(N[Si](C)(C)C(C)(C)C)N=CN=C32)C(O[Si](C)(C)C(C)(C)C)C1O[Si](C)(C)C(C)(C)C | 4308.8 | Standard polar | 33892256 | N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide,4TBDMS,isomer #2 | CCN(C=O)C(O[Si](C)(C)C(C)(C)C)C1OC(N2C=NC3=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N=CN=C32)C(O[Si](C)(C)C(C)(C)C)C1O | 3730.5 | Semi standard non polar | 33892256 | N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide,4TBDMS,isomer #2 | CCN(C=O)C(O[Si](C)(C)C(C)(C)C)C1OC(N2C=NC3=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N=CN=C32)C(O[Si](C)(C)C(C)(C)C)C1O | 3884.1 | Standard non polar | 33892256 | N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide,4TBDMS,isomer #2 | CCN(C=O)C(O[Si](C)(C)C(C)(C)C)C1OC(N2C=NC3=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N=CN=C32)C(O[Si](C)(C)C(C)(C)C)C1O | 4172.9 | Standard polar | 33892256 | N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide,4TBDMS,isomer #3 | CCN(C=O)C(O[Si](C)(C)C(C)(C)C)C1OC(N2C=NC3=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N=CN=C32)C(O)C1O[Si](C)(C)C(C)(C)C | 3737.2 | Semi standard non polar | 33892256 | N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide,4TBDMS,isomer #3 | CCN(C=O)C(O[Si](C)(C)C(C)(C)C)C1OC(N2C=NC3=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N=CN=C32)C(O)C1O[Si](C)(C)C(C)(C)C | 3885.2 | Standard non polar | 33892256 | N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide,4TBDMS,isomer #3 | CCN(C=O)C(O[Si](C)(C)C(C)(C)C)C1OC(N2C=NC3=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N=CN=C32)C(O)C1O[Si](C)(C)C(C)(C)C | 4153.5 | Standard polar | 33892256 | N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide,4TBDMS,isomer #4 | CCN(C=O)C(O)C1OC(N2C=NC3=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N=CN=C32)C(O[Si](C)(C)C(C)(C)C)C1O[Si](C)(C)C(C)(C)C | 3758.7 | Semi standard non polar | 33892256 | N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide,4TBDMS,isomer #4 | CCN(C=O)C(O)C1OC(N2C=NC3=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N=CN=C32)C(O[Si](C)(C)C(C)(C)C)C1O[Si](C)(C)C(C)(C)C | 3907.5 | Standard non polar | 33892256 | N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide,4TBDMS,isomer #4 | CCN(C=O)C(O)C1OC(N2C=NC3=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N=CN=C32)C(O[Si](C)(C)C(C)(C)C)C1O[Si](C)(C)C(C)(C)C | 4213.6 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide GC-MS (Non-derivatized) - 70eV, Positive | splash10-0uk9-7902000000-f5c4aa95fbcc4c64e75e | 2021-09-24 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide GC-MS (TMS_1_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide GC-MS (TMS_1_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide GC-MS (TMS_1_3) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide GC-MS (TMS_1_4) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide GC-MS (TMS_2_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide GC-MS (TMS_2_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide GC-MS (TMS_2_3) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide GC-MS (TMS_2_4) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide GC-MS (TMS_2_5) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide GC-MS (TMS_2_6) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide GC-MS (TMS_2_7) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide GC-MS (TMS_3_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide GC-MS (TMS_3_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide GC-MS (TMS_3_3) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide GC-MS (TMS_3_4) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide GC-MS (TMS_3_5) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide GC-MS (TMS_3_6) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide GC-MS (TMS_3_7) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide GC-MS (TBDMS_1_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide GC-MS (TBDMS_1_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide GC-MS (TBDMS_1_3) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide GC-MS (TBDMS_1_4) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - N-[[(2S,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-hydroxymethyl]-N-ethylformamide GC-MS (TBDMS_2_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum |
|
---|